Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
Explore the potential of Rejoyn™, a digital therapeutic now cleared by the FDA, which has shown to significantly reduce depressive symptoms in adults as an adjunct to traditional outpatient care, without any reported adverse events.
Psychiatry April 9th 2024
British Medical Journal
The study elucidates the substantial impact of exercise, particularly walking or jogging, yoga, and strength training, in alleviating depressive symptoms, advocating for their inclusion as principal treatments in depression care, reflecting a broadened approach to mental health management.
Psychiatry March 19th 2024
Johns Hopkins Medicine
Johns Hopkins psychiatrists are spearheading a novel educational initiative, ADAP Jr. High, to address the critical gap in middle schoolers’ understanding of anxiety and depression, offering structured lessons and coping strategies to empower young students.
Family Medicine/General Practice March 12th 2024
Psychiatrist.com
This study emphasizes the potential of MSK1 methylation levels and executive function as key indicators in predicting suicidal ideation among adolescents with major depressive disorder, providing a new dimension to our understanding of suicide risk factors in this age group.
Pediatrics March 5th 2024
The New England Journal of Medicine
Treatment-resistant depression in older adults requires a nuanced approach, considering coexisting medical and psychiatric conditions. These insights highlight the significance of collaborative care models and the potential of augmentation strategies in achieving remission.
Clinical Pharmacology February 21st 2024
Consultant360
In this video, Dr. Charles Raison reveals how hyperthermia may harness the body’s immune response to combat major depressive disorder, suggesting a potential shift in non-pharmacological treatment strategies.
Psychiatry February 13th 2024